Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant

Clinical Transplantation

Volumn 23, Issue 2, 2009, Pages 191-198

  Biselli, Maurizio ^a   Vitale, Giovanni ^a   Gramenzi, Annagiulia ^a   Riili, Anna ^a   Berardi, Sonia ^a   Cammà, Carlo ^b   Scuteri, Alessandra ^a   Morelli, Maria Cristina ^a   Grazi, Gian Luca ^a   Pinna, Antonio Daniele ^a   Andreone, Pietro ^a   Bernardi, Mauro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Calcineurin inhibitors; Immunosuppression; Liver transplantation; Mycophenolate mofetil; Renal dysfunction

Indexed keywords

CREATININE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANGINA PECTORIS; ANXIETY; ARTERIAL PRESSURE; ARTICLE; ASTHENIA; AUTONOMIC NEUROPATHY; BILE DUCT OBSTRUCTION; BONE MARROW DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMMON BILE DUCT STONE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INFECTION; INSOMNIA; KIDNEY DYSFUNCTION; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG EMBOLISM; MALE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA AND VOMITING; PREDICTION; PRIORITY JOURNAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; CALCINEURIN; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TACROLIMUS; TREATMENT OUTCOME;

EID: 64349085834     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.00965.x     Document Type: Article

References (35)

1. Moreno JM, Cuervas-Mons V, Rubio E et al. Chronic renal dysfunction after liver transplantation in adult patients: Prevalence, risk factors and impact on mortality. Transplant Proc 2003: 35: 1907.
2. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003: 9: 741.
3. Gonwa TA, Mai ML, Melton LB et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: Risk of development and treatment. Transplantation 2001: 72: 1934.
4. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003: 349: 931.
5. Sandborn WJ, Hay JE, Porayko MK et al. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology 1994: 19: 925.
6. Chan CY, Das Gupta K, Baker AL. Cyclosporin A: Drug discontinuation for the management of long-term toxicity after liver transplantation. Hepatology 1996: 24: 1085.
7. Barkmann A, Nashan B, Schmidt HH et al. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. Transplantation 2000: 69: 1886.
8. Neau-Cransac M, Morel D, Bernard PH et al. Renal failure after liver transplantation: Outcome after calcineurin inhibitor withdrawal. Clin Transplant 2002: 16: 368.
9. Cantarovich M, Tzimas GN, Barkun J, Deschenes M, Alpert E, Tchervenkov J. Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction. Transplantation 2003: 76: 98.
10. Raimondo ML, Dagher L, Papatheodoridis GV et al. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation 2003: 75: 186.
11. Gonwa TA. Treatment of renal dysfunction after orthotopic liver transplantation: Options and outcomes. Liver Transpl 2003: 9: 778.
12. Pfitzmann R, Klupp J, Langrehr JM et al. Mycophenolate mofetil for immunosuppression after liver transplantation: A follow-up study of 191 patients. Transplantation 2003: 76: 130.
13. Koch RO, Graziadei IW, Schulz F et al. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction. Transpl Int 2004: 17: 518.
14. Moreno Planas JM, Cuervas-Mons Martinez V, Rubio Gonzalez E et al. Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant 2004: 4: 1650.
15. Jain A, Vekatramanan R, Eghtesad B et al. Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation. Transplantation 2005: 80: 859.
16. Hong MKh, Angus PW, Jones RM, Vaughan RB, Gow PJ. Predictors of improvement in renal function after calcineurin inhibitor withdrawal for post-liver transplant renal dysfunction. Clin Transplant 2005: 19: 193.
17. Schlitt HJ, Barkmann A, Boker KH et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: A randomised controlled study. Lancet 2001: 357: 587.
18. Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001: 357: 609.
19. Beckebaum S, Cicinnati VR, Klein CG et al. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: Preliminary results of an open prospective study. Transplant Proc 2004: 36: 2671.
20. Reich DJ, Clavien PA, Hodge EE, MMF Renal Dysfunction after Liver Transplantation Working Group. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: Randomized, prospective, multicenter pilot study results. Transplantation 2005: 80: 18.
21. Bilbao I, Castells L, Rojas L et al. Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients. Int Immunopharmacol 2006: 6: 1977.
22. Orlando G, Baiocchi L, Cardillo A et al. Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia and hypertension. Liver Transpl 2007: 13: 46.
23. Pageux GP, Rostaing L, Calmus Y et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl 2006: 12: 1755.
24. Levey AS, Coresh J, Balk E et al. National kidney foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 2003: 139: 137.
25. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976: 16: 31.
26. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002: 39: S1.
27. CERMET (Certification and research for quality) Soc. Cons. a.r.l.; Health Service Conformity Certificate, registration no 1200-S2, last modification date 2006-12-31; http://www.cermet.it.
28. Farges O, Saliba F, Farhamant H et al. Incidence of rejection and infection after liver transplantation as a function of the primary disease: Possible influence of alcohol and polyclonal immunoglobulins. Hepatology 1996: 23: 240.
29. McTaggart RA, Terralt NA, Vardanian AJ, Bostrom A, Feng S. Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation. Liver Transpl 2004: 10: 975.
30. Falkenhain ME, Cosio FG, Sedmak DD. Progressive injury in kidneys from heart and liver transplant recipients receiving cyclosporine. Transplantation 1996: 62: 364.
31. Monsour HP, Wood RP, Dyer CH, Galati JS, Ozaki CF, Clark JH. Renal insufficiency and hypertension as long-term complications in liver transplantation. Semin Liver Dis 1995: 15: 123.
32. Romero F, Rodriguez-Iturbe B, Parra G, Gonzalez L, Herrera-Acosta J, Tapia E. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 1999: 55: 945.
33. Badid C, Vincent M, Mcgregor B et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 2000: 58: 51.
34. McKenzie N, Keown P, Stiller C, Kostuk W, Campbell C, Keith F. Effects of cyclosporine on renal function following orthotopic heart transplantation. J Heart Transplant 1985: 4: 400.
35. Moss NG, Powell SL, Falk RJ. Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats. Proc Natl Acad Sci U S A 1985: 82: 8222.